DK2668210T3 - Anti-kit antistoffer og anvendelser deraf - Google Patents

Anti-kit antistoffer og anvendelser deraf Download PDF

Info

Publication number
DK2668210T3
DK2668210T3 DK12740001.8T DK12740001T DK2668210T3 DK 2668210 T3 DK2668210 T3 DK 2668210T3 DK 12740001 T DK12740001 T DK 12740001T DK 2668210 T3 DK2668210 T3 DK 2668210T3
Authority
DK
Denmark
Prior art keywords
kit antibodies
antibodies
kit
Prior art date
Application number
DK12740001.8T
Other languages
English (en)
Inventor
Yaron Hadari
Susanne Radke
Joseph Schlessinger
Yoshihisa Suzuki
Elizabeth M Mandel-Bausch
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Application granted granted Critical
Publication of DK2668210T3 publication Critical patent/DK2668210T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
DK12740001.8T 2011-01-26 2012-01-25 Anti-kit antistoffer og anvendelser deraf DK2668210T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161436483P 2011-01-26 2011-01-26
US201161507430P 2011-07-13 2011-07-13
US201161537482P 2011-09-21 2011-09-21
PCT/US2012/022471 WO2012103165A2 (en) 2011-01-26 2012-01-25 Anti-kit antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DK2668210T3 true DK2668210T3 (da) 2020-08-24

Family

ID=46544334

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12740001.8T DK2668210T3 (da) 2011-01-26 2012-01-25 Anti-kit antistoffer og anvendelser deraf

Country Status (6)

Country Link
US (6) US9540443B2 (da)
EP (2) EP3763740A1 (da)
AR (1) AR085091A1 (da)
DK (1) DK2668210T3 (da)
TW (1) TW201242978A (da)
WO (1) WO2012103165A2 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
CN104812775B (zh) * 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
BR112015021134A2 (pt) 2013-03-15 2017-10-10 Novartis Ag conjugados de fármaco e anticorpo
WO2015050959A1 (en) * 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015067667A1 (en) * 2013-11-05 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Human neutralizing anti-kit antibodies and uses thereof
WO2015112822A1 (en) * 2014-01-24 2015-07-30 Kolltan Pharmaceuticals, Inc. Antibody-drug conjugates targeting kit receptor and uses thereof
EP3145543A4 (en) 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
MX2018015684A (es) 2016-06-17 2019-08-29 Magenta Therapeutics Inc Composiciones y metodos para el agotamiento de celulas cd117.
CN110099697B (zh) 2016-12-21 2023-11-28 诺华股份有限公司 用于消融造血干细胞的抗体药物缀合物
RU2766582C2 (ru) 2016-12-23 2022-03-15 Ремд Биотерапьютикс, Инк. Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
IL268058B2 (en) 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for depleting cd137 plus cells
EP3700568A4 (en) * 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
US10882915B2 (en) * 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
GB201802201D0 (en) 2018-02-09 2018-03-28 Ultrahuman Five Ltd Binding agents
EP3959243A4 (en) * 2019-04-24 2023-04-12 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND USES THEREOF
KR20230150275A (ko) * 2021-01-22 2023-10-30 셀덱스 쎄라퓨틱스, 인크. 항-kit 항체 및 이의 용도
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20260048121A1 (en) * 2023-01-05 2026-02-19 Dana-Farber Cancer Institute, Inc. Epitope engineering of cd38 cell-surface receptors
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (314)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5108912A (en) 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5268358A (en) 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US20050276784A1 (en) 1990-08-27 2005-12-15 Solan-Kettering Institute For Cancer Research Ligand for the c-kit receptor and methods of use thereof
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
EP0584082B1 (en) 1991-01-31 2000-05-31 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
JP3213314B2 (ja) 1991-04-05 2001-10-02 ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン 幹細胞因子レセプターに対するモノクローナル抗体
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5545533A (en) 1991-05-25 1996-08-13 Boehringer Mannheim Gmbh Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
DE4205148A1 (de) 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen c-kit
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
CA2124958C (en) 1991-12-02 2007-02-13 Vanitha Ramakrishnan Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
EP0548867A2 (en) 1991-12-23 1993-06-30 Yeda Research And Development Co. Ltd. Soluble stem cell factor (SFC)-receptor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6001803A (en) 1992-04-23 1999-12-14 Sloan-Kettering Institute For Cancer Research Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
WO1995002420A2 (en) 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Prodrugs of protein tyrosine kinase inhibitors
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
US5925376C1 (en) 1994-01-10 2001-03-20 Madalene C Y Heng Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
US5618709A (en) 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5911995A (en) 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
ATE331438T1 (de) 1995-01-17 2006-07-15 Brigham & Womens Hospital Rezeptorspezifischer transepithelealer transport von immunogenen
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5998596A (en) 1995-04-04 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of protein kinase activity by aptameric action of oligonucleotides
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
ES2268705T3 (es) 1995-06-01 2007-03-16 Kishimoto, Tadamitsu Inhibidor del crecimiento de celulas leucemicas que contienen un derivado oligonucleotidico antisentido frente al gen del tumor de wiloms (wt1).
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6936259B2 (en) 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US6127366A (en) 1995-11-22 2000-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EE03484B1 (et) 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
DE19600589C1 (de) 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
US5958769A (en) 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
AU703203B2 (en) 1996-01-30 1999-03-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU704087B2 (en) 1996-01-30 1999-04-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5910417A (en) 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
US5648239A (en) 1996-06-21 1997-07-15 Incyte Pharmaceuticals, Inc. Human camp-dependent protein kinase inhibitor homolog
AU2710597A (en) 1996-06-27 1998-01-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
NZ334613A (en) 1996-08-12 2002-02-01 Welfide Corp Pharmaceutical agents comprising Rho kinase inhibitor
US5945429A (en) 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US6040305A (en) 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6093737A (en) 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
EP0975603A1 (en) 1997-01-29 2000-02-02 Zeneca Limited Inhibitors of farnesyl protein transferase
ZA981080B (en) 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
WO1998041090A1 (en) 1997-03-19 1998-09-24 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6051582A (en) 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
DE19727814C1 (de) 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
EA002525B1 (ru) 1997-08-15 2002-06-27 Сефалон Инк. Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6555367B1 (en) 1997-10-10 2003-04-29 The United States Of America As Represented By The Department Of Health And Human Services Complex of biotinylated viral vector and ligand for targeted gene delivery
US6103723A (en) 1997-10-17 2000-08-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6342765B1 (en) 1997-10-22 2002-01-29 Astrazeneca Uk Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
AU9452998A (en) 1997-10-22 1999-05-10 Zeneca Limited Imidazole derivatives and their use as farnesyl protein transferase inhibit ors
ES2303358T3 (es) 1997-11-03 2008-08-01 Human Genome Sciences, Inc. Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
US6124465A (en) 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US6268363B1 (en) 1997-11-28 2001-07-31 Lg Chemical Ltd. Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
US6054466A (en) 1997-12-04 2000-04-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6335156B1 (en) 1997-12-18 2002-01-01 The Johns Hopkins University School Of Medicine 14-3-3σ arrests the cell cycle
DE69904302T2 (de) 1998-02-02 2003-08-14 Lg Chemical Ltd., Seoul/Soul Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
NZ507165A (en) 1998-04-27 2003-06-30 Warner Lambert Co Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
EP1073464B1 (en) 1998-04-28 2004-10-06 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
US6034053A (en) 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6362188B1 (en) 1998-12-18 2002-03-26 Schering Corporation Farnesyl protein transferase inhibitors
FR2787327B1 (fr) 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
US6432959B1 (en) 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
JP2002544123A (ja) 1999-04-14 2002-12-24 スミスクライン・ビーチャム・コーポレイション エリトロポイエチン受容体抗体
US6143766A (en) 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
US6989248B2 (en) 1999-05-06 2006-01-24 The Trustees Of Columbia University In The City Of New York Methods of use of compounds which inhibit the stem cell signaling pathway
US6576812B1 (en) 1999-05-06 2003-06-10 The Trustees Of Columbia University In The City Of New York Compound screening assays using a transgenic mouse model of human skin diseases
US6458935B1 (en) 1999-06-23 2002-10-01 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
WO2001034201A2 (en) 1999-11-12 2001-05-17 Advanced Research And Technology Institute, Inc. Methods for inhibiting neurofibromatosis type 1 (nf1)
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
JP5004392B2 (ja) 1999-12-22 2012-08-22 スージェン， インク． インドリノン化合物を用いてｃ−ｋｉｔチロシン蛋白質キナーゼ機能を調節する方法
US6403581B1 (en) 2000-01-19 2002-06-11 American Cyanamid Company Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20110091428A1 (en) 2000-07-31 2011-04-21 New York Medical College Compositions of adult organ stem cells and uses thereof
US6914947B2 (en) 2001-02-28 2005-07-05 Telefonaktiebolaget L M Ericsson (Publ) Method and apparatus for handling time-drift
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP1378752A4 (en) 2001-04-13 2004-08-04 Chugai Pharmaceutical Co Ltd METHOD FOR QUANTIFYING ANTIGEN EXPRESSION
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1427810B9 (en) 2001-08-21 2012-04-25 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/scf/pakt status
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
EP1465925A4 (en) 2001-12-20 2006-02-08 Human Genome Sciences Inc "ANTIBODIES THAT IMMUNE SPECIFICALLY TO TRAIL RECEPTORS"
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
WO2003102017A2 (en) * 2002-06-03 2003-12-11 Centocor, Inc. Anti-relp fusion antibodies, compositions, methods and uses
WO2004002425A2 (en) 2002-06-28 2004-01-08 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
US7705045B2 (en) 2002-11-14 2010-04-27 Syntarga, B.V. Prodrugs built as multiple self-elimination-release spacers
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US9243064B2 (en) * 2003-01-31 2016-01-26 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
DK1594542T3 (da) 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
US20050281828A1 (en) 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
JP2007528723A (ja) 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
US7303893B1 (en) 2003-08-28 2007-12-04 Takeda San Diego, Inc. Crystallization of c-KIT tyrosine kinase leading to autoinhibited crystal structure
ATE516288T1 (de) 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
AU2004297988A1 (en) 2003-12-04 2005-06-23 Laboratoires Serono Sa Methods for identifying modulators of active KIT tyrosine kinase receptor
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
CA2558195C (en) 2004-03-01 2012-11-06 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
DE502005008373D1 (de) 2004-03-27 2009-12-03 Hanns-Georg Klein Polymorphismen im nod2/card15 gen
JP4939397B2 (ja) 2004-03-30 2012-05-23 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュ ユニバーシティ オブ エルサレム アレルギー性反応に関与する細胞を標的化するための二重特異性抗体、ならびにその組成物および使用
AU2005249396B2 (en) 2004-05-05 2011-10-20 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
US20080287309A1 (en) 2004-07-10 2008-11-20 Alexion Pharmaceuticals, Inc. Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
EP2476427B1 (en) * 2004-08-02 2018-01-17 Zenyth Operations PTY. Ltd. A method of treating cancer comprising a VEGF-B antagonist
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US20060088522A1 (en) 2004-09-10 2006-04-27 Wyeth Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
JP2008531557A (ja) 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
US20060222634A1 (en) 2005-03-31 2006-10-05 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
EP1879901B1 (en) 2005-04-21 2009-12-23 Spirogen Limited Pyrrolobenzodiazepines
ES2417065T3 (es) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
WO2007004060A2 (en) 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US20090136450A1 (en) 2005-08-01 2009-05-28 Ares Trading S.A. Therapy for neurological diseases
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
AU2006294554B2 (en) 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
WO2008048671A1 (en) 2006-10-18 2008-04-24 University Of Illinois Embryonic-like stem cells derived from adult human peripheral blood and methods of use
ATE427949T1 (de) 2005-10-05 2009-04-15 Spirogen Ltd 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
WO2007048067A2 (en) 2005-10-21 2007-04-26 Regents Of The University Of California C-kit oncogene mutations in melanoma
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US20090304625A1 (en) 2006-01-18 2009-12-10 Ahsan Husain Modulators of cardiac cell hypertrophy and hyperplasia
US8940784B2 (en) 2006-02-02 2015-01-27 Syntarga B.V. Water-soluble CC-1065 analogs and their conjugates
CN102861338A (zh) 2006-04-05 2013-01-09 诺瓦提斯公司 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
JP2010500283A (ja) 2006-05-31 2010-01-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
WO2007145840A2 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
CA2663614A1 (en) 2006-09-28 2008-04-10 Merck And Co., Inc. Amine base salts of saha and polymorphs thereof
CN101528744A (zh) * 2006-10-20 2009-09-09 Irm责任有限公司 用于调节c-kit和pdgfr受体的组合物和方法
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
PT3255061T (pt) 2006-11-03 2021-07-26 Univ Leland Stanford Junior Imunodepleção seletiva de nicho de células estaminais endógenas para enxerto
US20100029674A1 (en) 2006-11-17 2010-02-04 Innate Pharma, S.A. Methods of Using Phosphoantigen for the Treatment of Cancer
WO2008115300A1 (en) 2006-12-01 2008-09-25 Apocell, Inc. C-kit phosphorylation in cancer
EP2137216A2 (en) 2007-03-12 2009-12-30 Vasgene Therapeutics, Inc. Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2008118391A2 (en) 2007-03-27 2008-10-02 Synta Pharmaceuticals Corp. Triazinone and diazinone derivatives useful as hsp90 inhibitors
US20110268776A1 (en) 2007-04-25 2011-11-03 Schapira Jay N Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
WO2008150261A1 (en) 2007-06-04 2008-12-11 Wyeth Detection and quantitation of calicheamicin
AU2008262384B9 (en) 2007-06-05 2014-11-27 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof
ES2433379T3 (es) 2007-08-01 2013-12-10 Syntarga B.V. Análogos de CC-1065 sustituidos y sus conjugados
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
WO2009023246A2 (en) 2007-08-14 2009-02-19 Wake Forest University Health Sciences Pluripotent adult stem cells
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009073139A2 (en) 2007-11-28 2009-06-11 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
EP2222709B1 (en) 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2231186A4 (en) 2007-12-17 2012-08-08 Dyax Corp COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
WO2009135001A2 (en) 2008-04-30 2009-11-05 University Of Pittsburgh- Commonwealth System Of Higher Education Methods and compositions for regulating th2 and th17 responses
WO2009140452A2 (en) 2008-05-15 2009-11-19 University Of Miami Isolation of stem cell precursors and expansion in non-adherent conditions
RU2011100106A (ru) 2008-06-13 2012-10-27 Новартис АГ (CH) Замещенные бензимидазолы для лечения нейрофиброматоза
CA2729567C (en) 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
US20110293574A1 (en) 2008-09-26 2011-12-01 Chute John P Hematopoietic stem cell growth factor
AU2009307651A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Prostate stem cells and uses thereof
MX2011004625A (es) 2008-11-03 2011-07-20 Syntarga Bv Analogos cc-1065 novedosos y sus conjugados.
CN102282252B (zh) 2008-11-19 2017-07-04 人类起源公司 羊膜来源的贴壁细胞
WO2010065685A1 (en) 2008-12-04 2010-06-10 Cleveland Clinic Method of treating c-kit positive relapsed acute myeloid leukemia
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
AR076668A1 (es) 2009-05-12 2011-06-29 Pfizer Anticuerpos especificos para dkk-1 y sus usos
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US20120253017A1 (en) 2009-05-28 2012-10-04 Victoria Ballard Stem cell targeting
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
MX2012007745A (es) 2009-12-29 2012-11-23 Univ Yale Inhibidores de receptores del factor de crecimiento endotelial vascular (vegf) y metodos de uso de los mismos.
US20120328599A1 (en) 2010-01-14 2012-12-27 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
US20130011406A1 (en) * 2010-03-26 2013-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
IN2013MN01394A (da) 2011-01-06 2015-06-12 Complix Nv
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
PT2750713E (pt) 2011-10-14 2016-01-20 Genentech Inc Pirrolobenzodiazepinas e conjugados das mesmas
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
CN104812775B (zh) 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015112822A1 (en) 2014-01-24 2015-07-30 Kolltan Pharmaceuticals, Inc. Antibody-drug conjugates targeting kit receptor and uses thereof
EP3145543A4 (en) 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders

Also Published As

Publication number Publication date
WO2012103165A3 (en) 2013-01-03
US20170073422A1 (en) 2017-03-16
EP2668210A2 (en) 2013-12-04
US20240141063A1 (en) 2024-05-02
WO2012103165A2 (en) 2012-08-02
US11884699B2 (en) 2024-01-30
US20200385483A1 (en) 2020-12-10
US20140056905A1 (en) 2014-02-27
US20120189633A1 (en) 2012-07-26
EP2668210B1 (en) 2020-06-17
US10793639B2 (en) 2020-10-06
EP2668210A4 (en) 2015-09-02
US9540443B2 (en) 2017-01-10
US20190100598A1 (en) 2019-04-04
US10189907B2 (en) 2019-01-29
AR085091A1 (es) 2013-09-11
TW201242978A (en) 2012-11-01
EP3763740A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
CY2021036I1 (el) Αντισωματα anti-angptl3 και χρησεις αυτων
IL288203A (en) Meditopes and meditope-binding antibodies and uses thereof
HUS2300021I1 (hu) Anti-IL-36R antitestek
CY2020045I2 (el) Anti-pd-l1 αντισωματα και χρησεις αυτων
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
IL231777B (en) Antibodies against tl1a and uses thereof
DK3556774T3 (da) Anti-CD40-antistoffer og anvendelser deraf
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
LT2794654T (lt) Anti-phf-tau antikūnai ir jų panaudojimas
CO6811812A2 (es) Anticuerpo anti-b7-h3
CO7071096A2 (es) Anticuerpos anti-lgr5 e inmunoconjugados
BR112015002193A2 (pt) anticorpos anti-etbr e imunoconjugados
IL228347A0 (en) Antibodies directed against icos and uses thereof
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
BR112012030311A2 (pt) anticorpo
HUE038962T2 (hu) DLL3-ellenes antitest
CR20140127A (es) Anticuerpo anti-abtcr
BR112013002297A2 (pt) anticorpos humanizados seguros e funcionais
EP2629796A4 (en) ANTIBODY
IL238227A0 (en) Anti-c16orf54 antibodies and methods of use thereof
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
CO6841994A2 (es) Anticuerpos